Tuesday, December 1, 2020
Home Latest Pharma-News Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical...

Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program

November 11, 2020: Eli Lilly and Company will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at 11:00 a.m.

Eastern Standard Time and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program.

- Advertisement -

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at https://investor.lilly.com/webcasts-and-presentations.

A replay will also be available on the website following the conference call.



Please enter your comment!
Please enter your name here

19 + 3 =

Most Popular

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance...

AstraZeneca agreed to sell rights to Crestor to be divested to Grünenthal in Europe

December 01, 2020: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the...

AstraZeneca’sForxiga approved in Japan for chronic heart failure

November 30, 2020: AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving...

Moderna Announces the EC Approval for Initial 80 Million Doses of mRNA Vaccine Against COVID-19

November 25, 2020: "Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines...